# Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

> **NCT00100802** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 118 (actual)

## Conditions studied

- Anaplastic Astrocytoma
- Central Nervous System Neoplasm
- Glioblastoma
- Gliosarcoma
- Spinal Cord Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lomustine
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00100802
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-21
- **Primary completion:** 2012-09-01
- **Final completion:** 2017-06-30
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100802, "Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00100802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*